DPI-3290

DPI-3290
(IUPAC) ime
	(+)-3-((αR)-α-((2S,5R)-4-Alil-2,5-dimetil-1-piperazinil)-3-hidroksibenzil)-N-(3-fluorofenil)-N-metilbenzamid
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	5242141
Hemijski podaci
Formula	C30H34FN3O2
Mol. masa	487.607 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C30H34FN3O2/c1-5-15-33-19-22(3)34(20-21(33)2)29(24-10-7-14-28(35)17-24)23-9-6-11-25(16-23)30(36)32(4)27-13-8-12-26(31)18-27/h5-14,16-18,21-22,29,35H,1,15,19-20H2,2-4H3/t21-,22+,29-/m0/s1 ; Key: LZXRQLIIMYJZDA-KERYWQKISA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

DPI-3290 je lek koji se koristi u naučnim istraživanjima. On je potentan analgetik,^[3] koji zaziva neznatnu respiratornu depresiju.^[4]

DPI-3290 deluje kao agonist μ- i δ-opioidnog receptora, sa IC50 vrednošću od 6.2 nM na μ i 1.0 nM na δ.^[5]

Literatura

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Gengo, PJ; Pettit, HO; O'Neill, SJ; Wei, K; McNutt, R; Bishop, MJ; Chang, KJ (2003). „DPI-3290 (+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide. I. A mixed opioid agonist with potent antinociceptive activity”. The Journal of pharmacology and experimental therapeutics 307 (3): 1221–6. DOI:10.1124/jpet.103.054361. PMID 14534368.
↑ Gengo, PJ; Pettit, HO; O'Neill, SJ; Su, YF; McNutt, R; Chang, KJ (2003). „DPI-3290 (+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide. II. A mixed opioid agonist with potent antinociceptive activity and limited effects on respiratory function”. The Journal of pharmacology and experimental therapeutics 307 (3): 1227–33. DOI:10.1124/jpet.103.054429. PMID 14534367.
↑ Ananthan S. Opioid ligands with mixed mi/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS Journal. 2006 Mar 10;8(1):E118-25. DOI 10.1208/aapsj080114 PMID 16584118

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Gengo, PJ; Pettit, HO; O'Neill, SJ; Wei, K; McNutt, R; Bishop, MJ; Chang, KJ (2003). „DPI-3290 (+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide. I. A mixed opioid agonist with potent antinociceptive activity”. The Journal of pharmacology and experimental therapeutics 307 (3): 1221–6. DOI:10.1124/jpet.103.054361. PMID 14534368.

[4] Gengo, PJ; Pettit, HO; O'Neill, SJ; Su, YF; McNutt, R; Chang, KJ (2003). „DPI-3290 (+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide. II. A mixed opioid agonist with potent antinociceptive activity and limited effects on respiratory function”. The Journal of pharmacology and experimental therapeutics 307 (3): 1227–33. DOI:10.1124/jpet.103.054429. PMID 14534367.

[5] Ananthan S. Opioid ligands with mixed mi/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS Journal. 2006 Mar 10;8(1):E118-25. DOI 10.1208/aapsj080114 PMID 16584118

[3]

[4]

[1]

[2]

[5]